P. H. St George-Hyslop

What is he best known for?

The fields of study he is best known for:

• Gene
• Mutation
• Genetics

His primary areas of study are Genetics, Alzheimer's disease, Presenilin, Locus and Pathology. Gene, Gene mapping, Genetic linkage, Genetic marker and Chromosome 21 are the subjects of his Genetics studies. He has researched Alzheimer's disease in several fields, including Antibody, Dementia, Pharmacology and Peptide.

The study incorporates disciplines such as Early-onset Alzheimer's disease and Cell biology in addition to Presenilin. He studied Locus and Amyloid precursor protein that intersect with Amyloid beta, Molecular biology and Beta protein. The various areas that he examines in his Pathology study include Allele and Chromosome 17.

His most cited work include:

• Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease (3518 citations)
• Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. (3218 citations)
• Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene (1764 citations)

What are the main themes of his work throughout his whole career to date?

P. St George-Hyslop focuses on Genetics, Alzheimer's disease, Presenilin, Gene and Degenerative disease. Genetics is closely attributed to Disease in his work. P. St George-Hyslop combines subjects such as Pathogenesis, Allele frequency, Dementia, Age of onset and Apolipoprotein E with his study of Alzheimer's disease.

P. St George-Hyslop interconnects Endocrinology, Mutant, Point mutation and Cell biology in the investigation of issues within Presenilin. His work carried out in the field of Gene brings together such families of science as Molecular biology and Amyloid precursor protein. His PSEN2 study combines topics in areas such as Early-onset Alzheimer's disease and PSEN1.

He most often published in these fields:

• Genetics (64.17%)
• Alzheimer's disease (39.17%)
• Presenilin (41.67%)

What were the highlights of his more recent work (between 2001-2013)?

• Genetics (64.17%)
• Presenilin (41.67%)
• Alzheimer's disease (39.17%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Genetics, Presenilin, Alzheimer's disease, Disease and Amyloid precursor protein. Presenilin is a subfield of Internal medicine that P. St George-Hyslop investigates. His Alzheimer's disease research is multidisciplinary, incorporating perspectives in Immunization, Immunology, Genetically modified mouse, Pharmacology and Degenerative disease.

His Degenerative disease research is classified as research in Pathology. His work deals with themes such as Genetic counseling, Case-control study and PSEN2, which intersect with Mutation. His PSEN2 research is multidisciplinary, relying on both Missense mutation and Exon.

Between 2001 and 2013, his most popular works were:

• Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4−10 and inhibit cytotoxicity and fibrillogenesis (422 citations)
• Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4−10 and inhibit cytotoxicity and fibrillogenesis (422 citations)
• LRRK2 gene in Parkinson disease: Mutation analysis and case control association study (141 citations)

In his most recent research, the most cited papers focused on:

• Gene
• Mutation
• DNA

His primary scientific interests are in Alzheimer's disease, Genetics, Pharmacology, Immunology and Genetically modified mouse. Alzheimer's disease is the subject of his research, which falls under Pathology. When carried out as part of a general Genetics research project, his work on Allele, Proband and Gene is frequently linked to work in Penetrant, therefore connecting diverse disciplines of study.

His Pharmacology research incorporates elements of Peptide and Antibody, Immunization, Antigen. His research in Immunology intersects with topics in Cognitive decline, Cognitive disorder and Degenerative disease. His Genetically modified mouse research is multidisciplinary, incorporating elements of Neurogenesis, Neuropathology, PI3K/AKT/mTOR pathway and Latrepirdine.